CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma
- Citation:
- Cancer Res Commun vol 4 (3) 682-90
- Year:
- 2024
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Methodological:
- No
- Biospecimen:
- Yes
- SDC:
- No
- Book Volume:
- 13
- Parents:
- 3431
- Children:
- None
- Pharmas:
- Bayer, Bristol-Myers-Squibb, and Sanofi
- Grants:
- U10CA180821, U10CA180882, U24CA196171, UG1CA233180, UG1CA233253, UG1CA233290, UG1CA233327, UG1CA233373, U10CA180863 (CCTG), U10CA180820 (ECOG-ACRIN), U10CA189859, U10CA180888 (SWOG)
- Corr. Author:
- Authors:
- Ghassan K. Abou-Alfa Susan M. Geyer Andrew B. Nixon Federico Innocenti Qian Shi Priya Kumthekar Sawyer Jacobson Imane El Dika Amin Yaqubie Juan Lopez Binhui Huang Yi-Wei Tang Yujia Wen Lawrence H. Schwartz Anthony B. El-Khoueiry Jennifer J. Knox Lakshmi Rajdev Monica M. Bertagnolli Jeffrey A. Meyerhardt Eileen M. O'Reilly Alan P. Venook
- Networks:
- CA011, CA136, LAPS-IL036, LAPS-MA036, LAPS-NC007, LAPS-NC010, LAPS-NY016, MN022, NY021
- Study
- CALGB-80802
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: